Search results for "Immunologic"

showing 10 items of 1115 documents

LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION

1989

Abstract A metabolic monocyte defect appears to correlate with non-responsiveness to hepatitis B vaccine in many patients on haemodialysis. This defect prevents production of interleukin-2 during T-cell activation after antigen contact. Receptors for interleukin-2 are, however, expressed in greater numbers than in healthy subjects or uraemic responders to hepatitis B vaccination. In this study, ten uraemic patients, previous non-responders to vaccination against hepatitis B, were revaccinated with the same vaccine combined with one intramuscular injection (2·5 × 10 5 U) of natural human interleukin-2. Systemic production of antibodies against hepatitis B surface antigen was initiated in tho…

AdultMaleViral Hepatitis VaccinesInterleukin 2HBsAgHepatitis B vaccinePilot ProjectsImmunoenzyme TechniquesImmune systemAntigenmedicineHumansHepatitis B VaccinesAgedUremiaHepatitis B Surface Antigensbiologybusiness.industryImmunologic Deficiency SyndromesReceptors Interleukin-2General MedicineMiddle AgedHepatitis Bmedicine.diseaseVirologyVaccinationAntibody FormationImmunologybiology.proteinInterleukin-2FemaleAntibodybusinessmedicine.drugThe Lancet
researchProduct

Influence of Thymopentin on Antibody Response, and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B Vaccinati…

1990

We investigated the influence of thymopentin as an adjuvant for hepatitis B vaccination on in vitro monocyte and T cell function and in vivo antibody response in a prospective, placebo-controlled double-blind trial in 20 low- and nonresponders to hepatitis B vaccination on chronic hemodialysis. 50 mg thymopentin was given subcutaneously twice per week for 3 weeks, followed by 1 intramuscular injection of 40 micrograms HB-Vax and 3 subsequent injections of thymopentin. After 1 month, the patients were boostered with 40 micrograms HB-Vax. There was no significant difference in T cell and monocyte function after administration of thymopentin, as determined in vitro. After 3 months, 3 patients …

AdultMaleViral Hepatitis VaccinesT-Lymphocytesmedicine.medical_treatmentT cellThymopoietinsMonocytesAdjuvants ImmunologicRenal DialysismedicineHumansThymopentinProspective StudiesHepatitis B AntibodiesAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryMonocyteAntibody titerMiddle AgedHepatitis BHepatitis Bmedicine.diseasePeptide FragmentsThymus HormonesVaccinationmedicine.anatomical_structureImmunologyFemaleThymopentinIntramuscular injectionbusinessAdjuvantmedicine.drugNephron
researchProduct

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive …

2012

Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug …

AdultMalelcsh:Immunologic diseases. AllergyAnti-HIV AgentseducationVirulenceHIV InfectionsDrug resistanceBiologySettore MED/42 - Igiene Generale E ApplicataViruspolymorphism03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingVirologyGenotypeDrug Resistance Viraldrug-naivemedicineHumansProspective Studies030304 developmental biology0303 health sciencesPolymorphism Genetic030306 microbiologyResearchproteaseViral LoadVirologyReverse transcriptase3. Good healthCD4 Lymphocyte CountDrug-naïveInfectious Diseases3121 General medicine internal medicine and other clinical medicineImmunologybiology.proteinHIV-1FemaleAntibodylcsh:RC581-607Viral loadHIV-1 infected patientmedicine.drugPeptide HydrolasesRetrovirology
researchProduct

Family context of children with autism. Implications for emotional and social development

2019

Families of children with autism spectrum disorder (ASD) can be differentiated according to sociodemographics and environmental risk factors characterized by stress parental, the use of coping strategies and social support. The aim of this study was to analyze the behavioral, emotional and social manifestations of children with ASD, related to different types of families characterized according risk factors as families with "high risk", with "moderated risk" and with "low risk". Participants were 52 mothers and their children between 7 and 11 years old with ASD without intellectual disability. All mothers provided information about children's behavior through the Strengths and Difficulties …

AdultMalelcsh:Immunologic diseases. AllergyHealth Knowledge Attitudes Practicesocial adjustmentAutism Spectrum DisorderMothersautismlcsh:Medicinelcsh:Infectious and parasitic diseasesRisk Factorsprosocial behaviorSurveys and QuestionnairesHumansFamilyfamily risklcsh:RC109-216Affective SymptomsChildlcsh:RMiddle Agedemotional problemsFemalelcsh:RC581-607Stress Psychologicalconduct disordersMedicina (Buenos Aires)
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbi…

2008

Summary Background The treatment of allergic asthma by specific immunotherapy (SIT) is hampered by potential side-effects. Objective The aim of this study was to study the effect of omalizumab, a monoclonal anti-IgE antibody, in combination with SIT in patients with seasonal allergic rhinoconjunctivitis (SAR) and co-morbid seasonal allergic asthma (SAA) incompletely controlled by conventional pharmacotherapy. Methods A randomized, double-blind, placebo-controlled, multi-centre trial was performed to assess the efficacy and safety of omalizumab (Xolair®) vs. placebo in combination with depigmented SIT (Depigoid®) during the grass pollen season. Omalizumab or placebo was started 2 weeks befor…

AdultMalemedicine.medical_specialtyAdolescentCombination therapyImmunologyOmalizumabOmalizumabAntibodies Monoclonal HumanizedPlacebolaw.inventionYoung AdultPharmacotherapyDouble-Blind MethodRandomized controlled triallawForced Expiratory VolumeInternal medicineAnti-Allergic AgentsmedicineClinical endpointHumansImmunology and AllergyChildConjunctivitis AllergicAsthmaPlant Extractsbusiness.industryAntibodies MonoclonalRhinitis Allergic SeasonalAntigens PlantMiddle Agedmedicine.diseaseCombined Modality TherapyAsthmaAntibodies Anti-IdiotypicRespiratory Function TestsTreatment OutcomeDesensitization ImmunologicAsthma Control QuestionnaireQuality of LifePhysical therapyPollenFemalebusinessmedicine.drugClinical & Experimental Allergy
researchProduct

Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with imm…

2013

The objective of this study was to analyze the accuracy of abdominal ultrasonography (AUS) in the assessment of mucosal healing in patients with Crohn's disease (CD) receiving immunomodulators and/or biological treatment, with ileocolonoscopy as the reference standard.Thirty patients were included in a prospective longitudinal study. All patients underwent ileocolonoscopy and AUS before and after a minimum of one year of treatment. The Crohn's Disease Endoscopic Inflammatory Index of Severity (CDEIS) was used for endoscopic assessment whereas AUS was analyzed by means of bowel wall thickness, color Doppler grade and percentage of increase of parietal enhancement after contrast injection.In …

AdultMalemedicine.medical_specialtyAdolescentDoppler echocardiographySeverity of Illness IndexEndoscopy GastrointestinalYoung AdultIntestinal mucosaAdjuvants ImmunologicCrohn DiseaseMedicineHumansImmunologic FactorsProspective StudiesBiological response modifiersIntestinal MucosaUltrasonography Doppler ColorCrohn's diseasemedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaGastroenterologyMucous membraneMagnetic resonance imagingGeneral Medicinemedicine.diseaseEndoscopymedicine.anatomical_structureAbdominal ultrasonographyFemaleRadiologybusinessFollow-Up StudiesJournal of Crohn'scolitis
researchProduct

Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell tra…

2020

BACKGROUND: Enterovirus/rhinoviruses (EvRh) are the most common cause of respiratory virus infections in recipients of allogeneic stem cell transplantation (allo-HSCT).; OBJECTIVE: We sought to analyze the value of the immunodeficiency scoring index (ISI) in predicting lower respiratory tract disease (LRTD) progression and mortality in a prospective cohort of consecutive adult (> 16 years) allo-HSCT recipients with EvRh infection from December 1 2013 to December 1 2019 at two Spanish transplant centers.; RESULTS: We included 234 allo-HSCT recipients with 383 EvRh episodes. Out of 383 EvRh episodes, 98 (25%) had LRTD. Multivariate logistic regression analysis identified three independent fac…

AdultMalemedicine.medical_specialtyAdolescentRhinovirusmedicine.medical_treatmentHematopoietic stem cell transplantationcommunity acquired respiratory virus030230 surgerymedicine.disease_cause03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineallogeneic stem celltrasplantationmedicineHumansTransplantation HomologousProspective StudiesProspective cohort studyRespiratory Tract InfectionsImmunodeficiencyimmunodeficiency scoring indexAgedRetrospective StudiesTransplantationPicornaviridae InfectionsRespiratory tract infectionsbusiness.industryHematopoietic Stem Cell TransplantationImmunologic Deficiency SyndromesRespiratory infectionMiddle Agedmedicine.diseaseTransplantationInfectious DiseasesrhinovirusROC CurveSpainMultivariate AnalysisRespiratory virus030211 gastroenterology & hepatologyFemaleRhinovirusbusiness
researchProduct

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct

Immunoregulatory T-lymphocyte subset deficiency in newly diagnosed Type 1 (insulin-dependent) diabetes mellitus

1984

Humoral and cell-mediated disorders in Type 1 (insulin-dependent) diabetes suggest that an imbalance of immunoregulatory T-cell subsets exists. In 23 newly diagnosed (onset less than 3 months) and 21 long-standing Type 1 diabetic patients, T lymphocyte subsets were analyzed using monoclonal antibodies (OKT3, OKT4, OKT8, OKM1). The newly diagnosed patients showed a reduction with a significant difference from healthy controls in total T cells (OKT3+: 58.1 +/- 8.5% versus 70.7 +/- 8.0%), helper/inducer cells (OKT4+: 33.8 +/- 7.0% versus 47.1 +/- 8.3%), suppressor/cytotoxic cells (OKT8+: 18.5 +/- 7.3% versus 32 +/- 6.8%) and monocytes (OKM1+: 11.5 +/- 3.8% versus 19.9 +/- 5.2%) (p less than 0.…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classT-LymphocytesEndocrinology Diabetes and Metabolismchemical and pharmacologic phenomenaNewly diagnosedBiologyMonoclonal antibodymedicine.disease_causeT-Lymphocytes RegulatoryMonocytesAutoimmunityPathogenesisIslets of LangerhansLeukocyte CountDiabetes mellitusInternal medicineInternal MedicinemedicineHumansCytotoxic T cellChildType 1 diabetesImmunologic Deficiency SyndromesAntibodies MonoclonalT-Lymphocytes Helper-InducerT lymphocytemedicine.diseaseDiabetes Mellitus Type 1EndocrinologyFemaleT-Lymphocytes CytotoxicDiabetologia
researchProduct